Want to see RLYB full AI Analyst Report?
Top Page
Rallybio
(NASDAQ:RLYB)
Select Model
Select Model
Rating:57Neutral
Price Target:
$17.00
▲(0.71% Upside)
Action:Reiterated
Date:10/27/26
The score is held back primarily by weak underlying operating performance (low income statement quality despite improved TTM headline results), partially offset by a strong, low-leverage balance sheet and improved TTM cash flow. Technicals are largely neutral, while valuation appears low on P/E and corporate events add support due to the announced special cash distribution tied to the proposed merger.
Positive Factors
Low leverage
Essentially debt-free financing reduces solvency and interest burden risks while preserving flexibility to fund clinical programs or strategic actions. This conservative capital structure is particularly valuable for a pre-commercial biotech whose operating cash needs can remain uneven over several quarters.
Negative Factors
Pre-commercial revenue base
The absence of recurring product revenue leaves the company dependent on financing or future collaboration economics to support research and corporate costs. That limits visibility into self-funded growth and makes progress toward durable commercial cash generation dependent on successful clinical development.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Essentially debt-free financing reduces solvency and interest burden risks while preserving flexibility to fund clinical programs or strategic actions. This conservative capital structure is particularly valuable for a pre-commercial biotech whose operating cash needs can remain uneven over several quarters.
Read all positive factors
Rallybio (RLYB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$86.09M
Dividend Yield0%
Average Volume (3M)12.56K
Price to Earnings (P/E)3.5
Beta (1Y)1.04
Revenue Growth-35.61%
EPS GrowthN/A
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,312,584
10 Day Avg. Volume19,245
30 Day Avg. Volume12,556
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.53
Price to Sales (P/S)36.02
P/FCF Ratio-1.04
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue17.52
Enterprise Value/Gross Profit-2.36
Enterprise Value/Ebitda0.24
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rallybio Business Overview & Revenue Model
Company Description
Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon illnesses. Its most advanced therapeutic candidate, RLYB212, is a monoc...
How the Company Makes Money
Rallybio is a pre-commercial, clinical-stage biotechnology company and, as such, it has not historically generated recurring revenue from product sales. Its primary source of funding has been financing activities (e.g., proceeds from equity offeri...
Rallybio Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
78
Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 434.00K | 858.00K | 636.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.22M | 766.00K | -38.87M | -150.00K | 0.00 | -109.00K |
| EBITDA | 31.21M | -27.97M | -60.37M | -78.78M | -67.72M | -45.39M |
| Net Income | 26.81M | -8.98M | -57.77M | -74.56M | -66.65M | -47.01M |
Balance Sheet | ||||||
| Total Assets | 95.58M | 62.26M | 68.11M | 115.62M | 180.44M | 182.19M |
| Cash, Cash Equivalents and Short-Term Investments | 90.69M | 54.74M | 65.51M | 109.93M | 168.99M | 175.33M |
| Total Debt | 0.00 | 176.00K | 154.00K | 392.00K | 555.00K | 0.00 |
| Total Liabilities | 3.28M | 4.30M | 6.45M | 9.44M | 11.12M | 6.58M |
| Stockholders Equity | 92.30M | 57.96M | 61.65M | 106.18M | 169.32M | 175.60M |
Cash Flow | ||||||
| Free Cash Flow | 30.61M | -29.81M | -49.28M | -60.28M | -57.34M | -45.87M |
| Operating Cash Flow | 30.61M | -29.81M | -49.28M | -60.27M | -57.28M | -45.53M |
| Investing Cash Flow | 27.32M | 47.27M | 33.49M | 27.66M | -112.17M | -2.33M |
| Financing Cash Flow | 270.00K | 16.00K | 5.20M | 143.00K | 51.08M | 82.97M |
Rallybio Technical Analysis
Negative
16.88
Price Trends
16.79
Negative
16.46
Negative
12.83
Positive
Market Momentum
-0.18
Positive
37.89
Neutral
44.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RLYB, the sentiment is Negative. The current price of 16.88 is above the 20-day moving average (MA) of 16.64, above the 50-day MA of 16.79, and above the 200-day MA of 12.83, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 37.89 is Neutral, neither overbought nor oversold. The STOCH value of 44.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RLYB.
Rallybio Risk Analysis
Rallybio disclosed 82 risk factors in its most recent earnings report. Rallybio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rallybio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $86.09M | 3.47 | 36.35% | 0.00% | -35.61% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $14.85M | -0.26 | -67.15% | ― | ― | 57.48% | |
46 Neutral | $9.18M | -0.03 | -816.56% | ― | ― | 85.06% | |
44 Neutral | $5.18M | -0.33 | -394.24% | ― | ― | 90.37% | |
41 Neutral | $2.35M | >-0.01 | -201.49% | ― | ― | 99.41% | |
41 Neutral | $15.12M | -1.22 | -152.77% | ― | ― | 91.38% |
* Healthcare Sector Average
RLYB
Rallybio
15.99
10.41
186.71%
MBRX
Moleculin Biotech
8.75
-217.16
-96.13%
APVO
Aptevo Therapeutics
1.30
-23.90
-94.84%
CTXR
Citius Pharmaceuticals
0.54
-1.03
-65.54%
PCSA
Processa Pharmaceuticals
1.85
-7.01
-79.12%
ALLR
Allarity Therapeutics
0.95
-0.45
-32.14%
Rallybio Corporate Events
Business Operations and StrategyDividendsM&A TransactionsShareholder Meetings
Rallybio Declares Special Cash Distribution Amid Avenzo Merger
Positive
Oct 26, 2026
Rallybio’s board of directors on October 25, 2026, approved a special cash distribution tied to its planned merger with Avenzo Therapeutics, under which Avenzo will become a wholly owned subsidiary. The cash distribution is estimated at $82....
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
Rallybio CFO Transition Amid Pending Avenzo Therapeutics Merger
Neutral
Sep 9, 2026
On September 8, 2026, Rallybio Corporation announced that Chief Financial Officer Jonathan Lieber will shift to part-time employment effective September 15, 2026, while retaining his titles as CFO and Principal Financial Officer and maintaining hi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.